🟢 Azitra is trading 5% up in pre-market with no identified company-specific catalyst

Azitra is trading 5.14% up at $0.14 in pre-market on October 2, 2026, with no company-specific announcement found to explain the move.

• On October 1, the company said its ATR04-484 Phase 1/2 trial can advance to Cohort 2 after a safety review; available reporting does not link this news to the pre-market gain.
• Broader markets are higher, while the supplied biotech-sector context is negative; neither clearly explains the move.